Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
United Kingdom
Bristol Haematology and Oncology Centre, Bristol Edinburgh Cancer Research Centre, Edinburgh Leeds Teaching Hospitals NHS Trust, Leeds Cambridge University - Addenbrooke's Hospital, London University College London Hospital, London